HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wulf Dirk Leuschner Selected Research

Immunoglobulin Fc Fragments

1/2021Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wulf Dirk Leuschner Research Topics

Disease

3Neoplasms (Cancer)
01/2022 - 10/2017
1Leukemia
01/2021
1Infections
10/2017

Drug/Important Bio-Agent (IBA)

1AntibodiesIBA
01/2022
1Immunoglobulin Fc FragmentsIBA
01/2021
1Bispecific AntibodiesIBA
01/2021
1Proteins (Proteins, Gene)FDA Link
10/2017